## Megakaryon



\*Induced pluripotent stem cells

Target: Megakaryon Corporation


Outline: Development of platelet preparations using human induced pluripotent stem (hiPS) cells

(The platelet-preparation technology is not reliant on donated blood. It (1) can produce a stable supply of platelets, (2) has a high

safety profile, and (3) makes low-medical-cost blood transfusions possible)

Investment

Authorized investment: ¥3 billion (maximum)



Joint research and development Technology transfer



- Kyoto University (Center for iPS Cell Research and Application)
- The University of Tokyo (Institute of Medical Science)

- One of a small number of venture companies taking up the challenge of commercialization in the field of iPS cells, in which Japan is a world leader
- Artificially produced platelet preparations can overcome supply constraints and the risk of viral infection associated with dependence on donated blood